Apoptosis-inducing effect of chemotherapeutic agents is potentiated by soy isoflavone genistein, a natural inhibitor of nf-κb in bxpc-3 pancreatic cancer cell line

Pancreas

Volumn 28, Issue 4, 2004, Pages

  Li, Yiwei ^a   Ellis, Kerrie Lynn ^a   Ali, Shadan ^a   El Rayes, Basil F ^a   Nedeljkovic Kurepa, Ana ^a   Kucuk, Omer ^a   Philip, Philip A ^a   Sarkar, Fazlul H ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Apoptosis; Cisplatin; Docetaxel; Genistein; Nuclear factor B

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; DOCETAXEL; GENISTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; TAXOID;

APOPTOSIS; ARTICLE; CELL DIVISION; DRUG ANTAGONISM; DRUG COMBINATION; DRUG EFFECT; DRUG POTENTIATION; HUMAN; METABOLISM; PANCREAS TUMOR; PATHOLOGY; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL DIVISION; CELL LINE, TUMOR; CISPLATIN; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; GENISTEIN; HUMANS; NF-KAPPA B; PANCREATIC NEOPLASMS; TAXOIDS;

EID: 2942690157     PISSN: 08853177     EISSN: 15364828     Source Type: Journal    
DOI: 10.1097/00006676-200405000-00020     Document Type: Article

References (35)

1. Jemal A, Murray T, Samuels A, et al. Cancer statistics, 2003. CA Cancer J Clin. 2003;53:5-26.
2. Jacobs AD. Gemcitabine-based therapy in pancreas cancer: gemcitabine-docetaxel and other novel combinations. Cancer. 2002;95:923-927.
3. El Rayes BF, Zalupski MM, Shields AF, et al. Phase II study of gemcitabine, cisplatin, and infusional fluorouracil in advanced pancreatic cancer. J Clin Oncol. 2003;21:2920-2925.
4. Ganjoo KN, Gordon MS, Sandler AB, et al. A phase I study of weekly gemcitabine and docetaxel in patients with advanced cancer: a Hoosier Oncology Group Study. Oncology. 2002;62:299-304.
5. Lenzi R, Yalcin S, Evans DB, et al. Phase II study of docetaxel in patients with pancreatic cancer previously untreated with cytotoxic chemotherapy. Cancer Invest. 2002;20:464-472.
6. Hortobagyi GN. Recent progress in the clinical development of docetaxel (Taxotere). Semin Oncol. 1999;26:32-36.
7. Kurtz JE, Negrier S, Husseini F, et al. A phase II study of docetaxel-irinotecan combination in advanced pancreatic cancer. Hepatogastroenterology. 2003;50:567-570.
8. Philip PA, Zalupski MM, Vaitkevicius VK, et al. Phase II study of gemcitabine and cisplatin in the treatment of patients with advanced pancreatic carcinoma. Cancer. 2001;92:569-577.
9. Cascinu S, Gasparini G, Catalano V, et al. A phase I-II study of gemcitabine and docetaxel in advanced pancreatic cancer: a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD). Ann Oncol. 1999;10:1377-1379.
10. Evans TR, Lofts FJ, Mansi JL, et al. A phase II study of continuous-infusion 5-fluorouracil with cisplatin and epirubicin in inoperable pancreatic cancer. Br J Cancer. 1996;73:1260-1264.
11. Chuang SE, Yeh PY, Lu YS, et al. Basal levels and patterns of anticancer drug-induced activation of nuclear factor-kappaB (NF-kappaB), and its attenuation by tamoxifen, dexamethasone, and curcumin in carcinoma cells. Biochem Pharmacol. 2002;63:1709-1716.
12. Bian X, McAllister-Lucas LM, Shao F, et al. NF-kappa B activation mediates doxorubicin-induced cell death in N-type neuroblastoma cells. J Biol Chem. 2001;276:48921-48929.
13. Yeh PY, Chuang SE, Yeh KH, et al. Increase of the resistance of human cervical carcinoma cells to cisplatin by inhibition of the MEK to ERK signaling pathway partly via enhancement of anticancer drug-induced NF kappa B activation. Biochem Pharmacol. 2002;63:1423-1430.
14. Lin ZP, Boller YC, Amer SM, et al. Prevention of brefeldin A-induced resistance to teniposide by the proteasome inhibitor MG-132: involvement of NF-kappaB activation in drug resistance. Cancer Res. 1998;58:3059-3065.
15. Barnes S. Effect of genistein on in vitro and in vivo models of cancer. J Nutr. 1995;125:777S-783S.
16. Davis JN, Singh B, Bhuiyan M, et al. Genistein-induced upregulation of p21WAF1, downregulation of cyclin B, and induction of apoptosis in prostate cancer cells. Nutr Cancer. 1998;32:123-131.
17. Li Y, Upadhyay S, Bhuiyan M, et al. Induction of apoptosis in breast cancer cells MDA-MB-231 by genistein. Oncogene. 1999;18:3166-3172.
18. Li Y, Sarkar FH. Gene expression profiles of genistein-treated PC3 prostate cancer cells. J Nutr. 2002;132:3623-3631.
19. Davis JN, Kucuk O, Sarkar FH. Genistein inhibits NF-kappa B activation in prostate cancer cells. Nutr Cancer. 1999;35:167-174.
20. Davis JN, Kucuk O, Djuric Z, et al. Soy isoflavone supplementation in healthy men prevents NF-kappaB activation by TNF-α in blood lymphocytes. Free Radic Biol Med. 2001;30:1293-1302.
21. Li Y, Sarkar FH. Inhibition of nuclear factor kappaB activation in PC3 cells by genistein is mediated via Akt signaling pathway. Clin Cancer Res. 2002;8:2369-2377.
22. Ahlgren JD. Chemotherapy for pancreatic carcinoma. Cancer. 1996;78:654-663.
23. Casper ES, Green MR, Kelsen DP, et al. Phase II trial of gemcitabine (2,2'-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas. Invest New Drugs. 1994;12:29-34.
24. Rougier P, Adenis A, Ducreux M, et al. A phase II study: docetaxel as first-line chemotherapy for advanced pancreatic adenocarcinoma. Eur J Cancer. 2000;36:1016-1025.
25. Cortes JE, Pazdur R. Docetaxel. J Clin Oncol. 1995;13:2643-2655.
26. Ryan DP, Kulke MH, Fuchs CS, et al. A Phase II study of gemcitabine and docetaxel in patients with metastatic pancreatic carcinoma. Cancer. 2002;94:97-103.
27. Ducreux M, Rougier P, Pignon JP, et al. A randomised trial comparing 5-FU with 5-FU plus cisplatin in advanced pancreatic carcinoma. Ann Oncol. 2002;13:1185-1191.
28. Ganansia-Leymarie V, Bischoff P, Bergerat JP, et al. Signal transduction pathways of taxanes-induced apoptosis. Curr Med Chem Anticancer Agents. 2003;3:291-306.
29. Stein CA. Mechanisms of action of taxanes in prostate cancer. Semin Oncol. 1999;26:3-7.
30. Azuma M, Tamatani T, Ashida Y, et al. Cisplatin induces apoptosis in oral squamous carcinoma cells by the mitochondria-mediated but not the NF-kappaB-suppressed pathway. Oral Oncol. 2003;39:282-289.
31. Gonzalez VM, Fuertes MA, Alonso C, et al. Is cisplatin-induced cell death always produced by apoptosisMol Pharmacol. 2001;59:657-663.
32. Lian F, Bhuiyan M, Li YW, et al. Genistein-induced G2-M arrest, p21WAF1 upregulation, and apoptosis in a non-small-cell lung cancer cell line. Nutr Cancer. 1998;31:184-191.
33. Chawla-Sarkar M, Bauer JA, Lupica JA, et al. Suppression of NF-kappa B survival signaling by nitrosylcobalamin sensitizes neoplasms to the anti-tumor effects of Apo2L/TRAIL. J Biol Chem 2003.
34. Han SY, Choung SY, Paik IS, et al. Activation of NF-kappaB determines the sensitivity of human colon cancer cells to TNFα-induced apoptosis. Biol Pharm Bull. 2000;23:420-426.
35. Osaki S, Nakanishi Y, Takayama K, et al. Transfer of IkappaBα gene increase the sensitivity of paclitaxel mediated with caspase 3 activation in human lung cancer cell. J Exp Clin Cancer Res. 2003;22:69-75.